Skip to main content
SpringerLink
Log in

Should Adjuvant Therapy Remain the Standard of Care for Patients With Resected Adenocarcinoma of the Pancreas?

  • New Approaches to the Treatment of Hepatic Malignancies
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Adenocarcinoma of the pancreas continues to be a formidable disease. In the United States, patients who have had resected disease are generally offered adjuvant chemoradiation. The current National Comprehensive Cancer Network practice guidelines uniformly support this practice. We reviewed seven selected series to evaluate the efficacy of adjuvant therapy for patients who had resected adenocarcinoma of the pancreas. Current evidence-based analysis demonstrates that an adjuvant therapy regimen as a standard of care is lacking. We, therefore, believe that it should be used judiciously because its benefit is confined to only a fraction of patients treated by complete resection (R0); patients with residual microscopic disease (R1) derived negligible benefits. Given the financial constraints and the small effect that current therapies have on this fatal disease, clinicians should concentrate on developing novel therapies and new paradigms to address this age-old problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Jemal A, Thomas A, Murray T, et al. Cancer statistics 2003. CA Cancer J Clin 2003; 53: 5–26.

    Article  PubMed  Google Scholar 

  2. Gibbs JF, Smith JL, Douglass HO. Surgical treatment of pancreatic carcinoma. In: Rustgi AK, Crawford J, eds. Gastrointestinal Cancers: Biology and Clinical Management. Philadelphia: Saunders, 2003: 541–7.

    Google Scholar 

  3. National Comprehensive Cancer Network. Practice Guidelines in Oncology. Available at: http://www.nccn.org. 2002.

  4. Haslam JB, Cavanaugh PJ, Stroup SL. Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer 1973; 32: 1341–5.

    PubMed  CAS  Google Scholar 

  5. Moertel CG, Childs DS, Reitemeir RJ, et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1967; 2: 865–7.

    Google Scholar 

  6. The Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone or in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. Ann Surg 1979; 189: 205–8.

    Google Scholar 

  7. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899–903.

    CAS  PubMed  Google Scholar 

  8. Douglass HO Jr, Stablein DM. Ten-year follow-up of first generation surgical adjuvant studies of the Gastrointestinal Tumor Study Group. In: SE Salmon, ed. Adjuvant Therapy of Cancer VI. Philadelphia: Saunders, 1990: 405–15.

    Google Scholar 

  9. Douglass HO, Nava HR, Panahon A, et al. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 1987; 59: 2006–10.

    PubMed  Google Scholar 

  10. Bakkevold KE, Arnesjø B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater—results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993; 29A: 698–703.

    PubMed  CAS  Google Scholar 

  11. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC Gastrointestinal Tract Caner Cooperative Group. Ann Surg 1999; 230: 776–84.

    Article  CAS  PubMed  Google Scholar 

  12. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997; 225: 621–36.

    PubMed  CAS  Google Scholar 

  13. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s. Ann Surg 1997; 226: 248–60.

    Article  CAS  PubMed  Google Scholar 

  14. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576–85.

    Article  CAS  PubMed  Google Scholar 

  15. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234: 758–68.

    Article  CAS  PubMed  Google Scholar 

  16. Abrams RA, Lillemoe KD, Piantodosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet 2001; 358: 1565–6.

    Article  CAS  PubMed  Google Scholar 

  17. Edis AJ, Kiernan PD, Taylor WF. Attempted curative resection of ductal carcinoma of the pancreas. Mayo Clin Proc 1980; 55: 531–6.

    PubMed  CAS  Google Scholar 

  18. Pedrazzoli S, Dicarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Ann Surg 1998; 228: 508–17.

    Article  CAS  PubMed  Google Scholar 

  19. Dunn JA, Stocken DD, Almond J, et al. Meta-analysis of adjuvant chemoradiotherapy and chemotherapy for resectable pancreatic cancer including the final results of the ESPAC-1 trial (abstract 564). Proc Am Soc Clin Oncol 2002; 21: 42a.

    Google Scholar 

  20. Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg 1996; 224: 342–9.

    Article  CAS  PubMed  Google Scholar 

  21. Leach SD, Lee JE, Charnsangavej C, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998; 85: 611–7.

    Article  CAS  PubMed  Google Scholar 

  22. Koppa SD, ed. Current Clinical Trials–Oncology. National Cancer Institute PDQ. Triple I, Division of MediMedic-USA, Inc. 2002; 9:I-52–I-54.

  23. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996; 223: 273–9.

    PubMed  CAS  Google Scholar 

  24. Huang JJ, Yeo CJ, Sohn TA, et al. Quality of life and outcomes after pancreaticoduodenectomy. Ann Surg 2000; 231: 890–8.

    PubMed  CAS  Google Scholar 

  25. McLeod RS, Taylor BR, O’Connor BI, et al. Quality of life, nutritional status, and gastrointestinal hormone profile following the Whipple procedure. Am J Surg 1995; 169: 179–85.

    PubMed  CAS  Google Scholar 

  26. Melvin WS, Buekers KS, Muscarella P, et al. Outcome analysis of long-term survivors following pancreaticoduodenectomy. J Gastrointest Surg 1998; 2: 72–8.

    PubMed  CAS  Google Scholar 

  27. Gelber RD, Goldhirsch A, Cole BF. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group. Control Clin Trials 1993; 14: 485–99.

    PubMed  CAS  Google Scholar 

  28. Gelber RD, Goldhirsch A, Cole BF, Wieand HS, Schroeder G, Krook JE. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst 1996; 88: 1039–45.

    PubMed  CAS  Google Scholar 

  29. Parsons SK, Gelber S, Cole BF, et al. Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: a Q-TWiST analysis of the Pediatric Oncology Group study 8821. J Clin Oncol 1999; 17: 2144–52.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, New York

    Quyen D. Chu MD, Harold O. Douglass Jr MD & John F. Gibbs MD

  2. Department of Medical Oncology, Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, New York

    Nikhil Khushalani MD & Miland M. Javle MD

  3. Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Street, Buffalo, NY, 14263

    John F. Gibbs MD

Authors
  1. Quyen D. Chu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikhil Khushalani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miland M. Javle MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Harold O. Douglass Jr MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John F. Gibbs MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John F. Gibbs MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chu, Q.D., Khushalani, N., Javle, M.M. et al. Should Adjuvant Therapy Remain the Standard of Care for Patients With Resected Adenocarcinoma of the Pancreas?. Ann Surg Oncol 10, 539–545 (2003). https://doi.org/10.1245/ASO.2003.06.015

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2003.06.015

Key Words

Search

Navigation